2. Epigenetics
  3. Small Interfering RNA (siRNA)
  4. Givosiran

Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran can be used for the research of acute hepatic porphyria (AHP).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr. : 1639325-43-1

Größe Preis Verfügbarkeit Menge
1 mg Auf Lager
5 mg Angebot einholen
10 mg Angebot einholen
25 mg Angebot einholen
50 mg Angebot einholen
100 mg Angebot einholen
200 mg   Angebot einholen  
500 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Other Forms of Givosiran:

Givosiran Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Givosiran

Others

    Givosiran purchased from MedChemExpress. Usage Cited in: Am J Reprod Immunol. 2024 Aug;92(2):e13916.  [Abstract]

    Heme concentrations in the RL95-2 cells treated by succinate 2.5 mM for 24 h, then the supplement of 5 µM SDHB inhibitor (Fluopyam) or 1 µM ALAS1 inhibitor (Givosiran) for 24 h.

    • Biologische Aktivität

    • Reinheit & Dokumentation

    • Verweise

    • Kundenbewertung

    Beschreibung

    Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran can be used for the research of acute hepatic porphyria (AHP)[1][2].

    In Vivo

    Givosiran (10 mg/kg, s.c., single dose) effectively reduces ALAS1 mRNA levels in liver tissue and serum in rats with rapid onset and long-lasting inhibitory properties[2].
    Givosiran (3 mg/kg, s.c., twice weekly for 3 weeks) exhibits complete preventive effect in the rat acute intermittent porphyria (AIP) model[2].
    Givosiran (20 mg/kg, s.c., single dose) works faster and has stronger inhibition than standard Hemoglobin (HY-P2995) treatment in mice[2].
    Givosiran (1-10 mg/kg, s.c., single dose or once daily for 8 weeks) reduces serum and urinary ALAS1 levels in cynomolgus monkey, and repeated administration results in sustained inhibition that is reversible after drug discontinuation[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: AIP model induced by Phenobarbital established in SD rats[2]
    Dosage: 3 mg/kg
    Administration: Subcutaneous injection (s.c.), twice weekly for 3 weeks
    Result: Completely prevented inducible ALAS1 elevation and associated metabolite accumulation.
    Animal Model: AIP model induced by Phenobarbital established in T1/T2 AIP mice[2]
    Dosage: 20 mg/kg
    Administration: Subcutaneous injection (s.c.), single dose
    Result: Inhibited ALAS1 faster and stronger than Hemoglobin.
    Animal Model: AIP model induced by Phenobarbital established in cynomolgus monkey (M. fascicularis)[2]
    Dosage: 1 and 10 mg/kg (single dose); 5 mg/kg (8 weeks)
    Administration: Subcutaneous injection (s.c.), single dose or once daily for 8 weeks
    Result: Dose-dependently and reversibly inhibited ALAS1 levels and repeated dosing achieved sustained suppression.
    Molekulargewicht

    16300.60

    CAS. Nr.
    Appearance

    Solid

    Color

    White to off-white

    Sequence

    RNA, (Cm-sp-Am-sp-Gm-Am-Am-Am-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)C-Um-(2'-deoxy-2'-fluoro)C-Am-Um-Cm-Um-Um-Am), 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]- 14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)A-sp-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Gm-sp-Gm-sp-Um) (1:1)
    SMILES

    [Givosiran]
    Versand

    Room temperature in continental US; may vary elsewhere.
    Speicherung

    -20°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Reinheit & Dokumentation

    Purity: 96.95%

    SDS (252 KB)

    COA (251 KB) RP-HPLC (219 KB) MS (303 KB)

    Handling Instructions (2242 KB)
    Verweise
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Givosiran Related Classifications

    • Molaritätsrechner

    • Verdünnungsrechner

    Die Formel zur Berechnung von Molaritäten

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

    Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Givosiran1639325-43-1ALN-AS1Small Interfering RNA (siRNA)siRNAaminolevulinateALAS1mRNAδ-aminolevulinicacidporphobilinogenacuteintermittentporphyriaInhibitorinhibitorinhibit

    Ihre kürzlich angesehenen Produkte:

    Online-Anfrage

    Your information is safe with us. * Required Fields.

    Produktname

    		  

    Requested Quantity *

    Name des Antragstellers *

    		 

    Anrede

    E-Mail-Addresse *

    		 

    Telefonnummer *

    Department

    		 

    Name der Organisation *

    City

    Bundesland

    Country or Region *

    		      

    Bemerkungen

    Massenanfrage

    Inquiry Information

    Produktname:
    Givosiran
    Art. -Nr.:
    HY-132610
    Menge:
    MCE Japan Authorized Agent:

    Kundenbewertung

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Produktname

    		  

    Lot #

    Name des Antragstellers *

    		 

    E-Mail-Addresse *

    Telefonnummer

    		 

    Department *

    Name der Organisation *

    		 

    Country or Region *

    Bemerkungen

    SAFETY DATA SHEET (SDS)

    English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.